detect
respiratori
virus
clinic
sampl
import
patient
manag
promot
ration
use
antivir
antibiot
implement
infect
control
measur
epidemiolog
studi
respiratori
virus
identifi
use
varieti
techniqu
includ
direct
antigen
test
nonimmunofluoresc
immunofluoresc
method
convent
rapid
cell
cultur
articl
present
overview
method
commonli
use
noncultur
method
membranebas
enzym
immunoassay
eia
optic
varieti
nonmolecular
approach
respiratori
viru
detect
includ
rapid
antigen
test
immunofluoresc
antibodi
test
convent
cell
cultur
rapid
cell
cultur
specimen
test
includ
nasopharyng
np
aspir
np
wash
np
swab
np
swab
plu
oropharyng
op
swab
viral
transport
media
vtm
liquid
specimen
sputum
tracheal
aspir
bronchoalveolar
lavag
sensit
viru
detect
method
vari
significantli
depend
sampl
type
time
sampl
collect
onset
symptom
patient
age
antigen
target
properti
viru
exampl
direct
detect
recoveri
respiratori
virus
better
np
aspir
test
compar
np
op
swab
influenza
b
tend
present
lower
amount
influenza
children
gener
shed
higher
titer
viru
longer
time
period
adult
methodolog
cost
advantag
disadvantag
nonmolecular
test
method
describ
detail
review
leland
ginocchio
summar
tabl
immunoassay
oia
thermo
electron
corp
boulder
co
immunochromatographiclater
flow
iclf
system
techniqu
provid
rapid
result
gener
within
min
simpl
use
mani
waiv
statu
accord
clinic
laboratori
improv
act
clia
guidelin
perform
outsid
laboratori
set
emerg
depart
clinic
physician
offic
mani
assay
contain
intern
control
monitor
reagent
technic
perform
detect
differenti
influenza
b
major
disadvantag
test
limit
influenza
b
respiratori
syncyti
viru
rsv
gener
eia
oia
iclf
requir
approxim
viral
particl
obtain
posit
result
contrast
cell
cultur
molecular
amplif
assay
may
requir
viru
particl
rna
dna
target
respect
viru
detect
st
georg
et
al
numer
studi
demonstr
sensit
assay
vari
significantli
rang
influenza
rsv
compar
cell
cultur
leland
ginocchio
result
vari
due
studi
design
properti
assay
patient
popul
compar
test
method
caution
use
interpret
comparison
studi
result
sensit
nonif
rsv
antigen
test
higher
nonif
antigen
test
influenza
b
gener
higher
cell
cultur
due
labil
rsv
respiratori
season
assay
specif
rsv
influenza
nonif
antigen
test
high
respect
leland
ginocchio
howev
specif
posit
predict
valu
nonif
antigen
test
markedli
reduc
shorter
time
detect
compar
convent
cultur
detect
virus
replic
poorli
cell
cultur
requir
less
expertis
read
cpe
alway
sensit
detect
rsv
adenoviru
technic
time
stain
read
detect
limit
virus
test
precp
stain
isol
alway
avail
sampl
test
outsid
respiratori
season
time
period
nonif
antigen
test
use
caution
posit
result
confirm
dfa
cell
cultur
revers
transcriptas
polymeras
chain
reaction
also
good
laboratori
practic
confirm
first
season
posit
result
use
anoth
method
prefer
viral
cultur
supplement
test
also
consid
viral
isol
necessari
epidemiolog
studi
antivir
test
rule
coinfect
anoth
viru
particularli
person
underli
diseas
immun
suppress
sever
respiratori
diseas
final
laboratori
reevalu
perform
nonif
rapid
test
yearli
basi
circul
viral
strain
may
chang
affect
sensit
specif
assay
due
poor
perform
nonif
antigen
test
limit
scope
detect
primari
method
viral
antigen
detect
mani
laboratori
test
perform
cell
spot
made
directli
clinic
sampl
reagent
contain
viru
specif
fluoresc
label
monoclon
antibodi
fmab
pool
contain
fmab
multipl
virus
test
also
done
reflex
test
specimen
neg
nonif
antigen
test
posit
nonif
antigen
test
potenti
mix
infect
individu
fmab
respiratori
virus
also
avail
manufactur
compar
viral
cultur
overal
sensit
fmab
pool
report
approxim
leland
vari
significantli
depend
viru
compar
cell
cultur
sensit
rsv
detect
nonif
antigen
assay
higher
respiratori
virus
rang
fong
et
al
leland
ginocchio
less
sensit
cultur
adenoviru
rang
leland
leland
ginocchio
use
two
differ
fluorophor
overlap
spectra
label
differ
mab
pool
reagent
permit
simultan
detect
one
virus
cell
spot
dual
fmab
pool
avail
chemicon
intern
light
diagnost
simulfluor
reagent
detect
follow
combin
influenza
ainfluenza
b
parainfluenza
parainfluenza
rsvinfluenza
rsvparainfluenza
rsvinfluenza
b
parainfluenza
adenoviru
excel
sensit
specif
shown
dual
reagent
result
compar
individu
reagent
dhi
market
dual
fmab
pool
detect
rsvinfluenza
b
parainfluenza
adenoviru
duet
dfa
rsvrespiratori
viru
screen
kit
influenza
ainfluenza
b
rsv
parainfluenza
adenoviru
duet
dfa
influenza
arespiratori
viru
screen
kit
dhi
duet
reagent
compar
sensit
ultra
respiratori
reagent
dhi
individu
fmab
lotlikar
et
al
signific
benefit
use
dual
fmab
pool
reagent
may
provid
immedi
identif
viru
es
sampl
season
high
viru
activ
use
duallabel
reagent
screen
method
follow
reflex
test
use
individu
fmab
requir
reduc
time
final
result
amount
work
requir
mani
laboratori
perform
test
human
metapneumoviru
hmpv
primarili
pediatr
geriatr
immunocompromis
patient
hmpv
mab
avail
chemicon
intern
dhi
addit
ultra
reagent
dhi
incorpor
fmab
hmpv
ultra
respiratori
pool
reagent
landri
et
al
found
direct
stain
clinic
specimen
use
chemicon
hmpv
reagent
difficult
interpret
due
nonspecif
background
stain
studi
lotlikar
et
al
found
ultra
dhi
hmpv
specif
reagent
gave
compar
result
compar
nucleic
sequenc
base
amplif
assay
nuclisen
hmpv
asr
durham
nc
sensit
incorpor
hmpv
fmab
respiratori
pool
provid
rapid
method
screen
hmpv
along
seven
common
respiratori
virus
supplement
cultur
test
requir
virus
suspect
cell
cultur
primari
diploid
heteroploid
cell
use
combin
detect
common
respiratori
virus
leland
ginocchio
number
type
cultur
tube
inocul
depend
viru
es
suspect
predispos
clinic
condit
immunosuppress
cultur
tube
gener
incub
day
stationari
rotat
rack
cell
monolay
examin
daili
first
week
everi
day
second
week
presenc
cytopath
effect
cpe
type
cpe
cell
line
detect
indic
potenti
viru
es
sampl
identif
specif
viru
achiev
use
fmab
cpe
may
subtl
absent
primari
cultur
even
respiratori
viru
present
therefor
hemadsorpt
test
perform
detect
influenza
parainfluenza
virus
final
cultur
result
minnich
ray
cpe
posit
cell
spot
made
monolay
stain
fmab
identifi
viru
es
centrifugationenhanc
inocul
cell
monolay
grown
microwel
cluster
plate
coverslip
shell
vial
enhanc
time
recoveri
respiratori
virus
hugh
shell
vial
cluster
plate
examin
cpe
howev
gener
shell
vial
coverslip
cluster
plate
blind
stain
either
individu
fmab
pool
hr
post
inocul
sever
studi
demonstr
respiratori
virus
leland
ginocchio
rapidli
isol
shell
vial
landri
et
al
demonstr
shell
vial
combin
stain
mab
chemicon
use
detect
hmpv
rmix
tm
rapid
cell
cultur
techniqu
dhi
use
patent
cell
monolay
compris
mink
lung
cell
support
growth
common
respiratori
virus
multipl
vial
cluster
plate
inocul
centrifug
incub
co
rmix
tm
monolay
stain
hr
use
fmab
pool
direct
adenoviru
rsv
influenza
b
parainfluenza
fluoresc
detect
second
rmix
well
vial
use
make
cell
spot
stain
individu
fmab
mani
laboratori
discard
cultur
hr
major
posit
cultur
detect
within
time
period
barenfang
et
al
fong
et
al
altern
third
well
vial
screen
addit
day
cpe
produc
virus
detect
fmab
pool
eg
enteroviru
herp
simplex
viru
cytomegaloviru
slow
grow
low
titer
part
mix
infect
sever
studi
compar
detect
respiratori
virus
rmix
cultur
tube
cell
cultur
nonif
antigen
test
leland
ginocchio
except
rsv
adenoviru
studi
demonstr
equal
enhanc
detect
common
respiratori
virus
use
rmix
tm
compar
nonmolecular
base
method
leland
ginocchio
rmix
tm
cell
shown
support
growth
virus
typic
isol
cell
cultur
includ
hmpv
setterquist
grey
lotlikar
et
al
sar
coronaviru
gillimross
et
al
rmix
cell
dhi
compris
madin
darbi
canin
kidney
mdck
cell
support
growth
sar
cov
gillimross
et
al
coronavirus
sensit
isol
respiratori
virus
wilkey
et
al
rmix
tm
rmix
cultur
support
growth
avian
influenza
strain
de
jong
hien
one
major
benefit
use
rapid
cultur
versu
convent
cultur
method
signific
improv
time
posit
result
versu
barenfang
et
al
hr
posit
versu
day
posit
fong
et
al
summari
nonmolecular
method
avail
detect
common
respiratori
virus
mani
instanc
cell
cultur
longer
consid
gold
standard
combin
method
often
necessari
provid
optim
diagnost
method
select
depend
target
viru
es
patient
popul
clinic
circumst
rapid
report
result
essenti
permit
prompt
institut
infect
control
measur
effect
antivir
therapi
reduc
unnecessari
use
antibiot
tm
bioscienc
luminex
consult
honoraria
clinic
trial
grant
consult
honoraria
clinic
trial
grant
diagnosi
hybrid
clinic
trial
grant
honoraria
